Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
2018 |
| gptkbp:ATCCode |
N02CD03
|
| gptkbp:brand |
gptkb:Emgality
|
| gptkbp:CASNumber |
1807928-93-3
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
galcanezumab
|
| gptkbp:indication |
episodic cluster headache
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG4 monoclonal antibody
|
| gptkbp:mechanismOfAction |
CGRP antagonist
|
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
hypersensitivity
injection site reactions |
| gptkbp:target |
gptkb:calcitonin_gene-related_peptide
|
| gptkbp:UNII |
Q1J0XQ6F1T
|
| gptkbp:usedFor |
migraine prevention
|
| gptkbp:bfsParent |
gptkb:Emgality
|
| gptkbp:bfsLayer |
6
|